{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:48:49Z","timestamp":1789051729178,"version":"build-2803163510"},"reference-count":87,"publisher":"Bioscientifica","issue":"7","license":[{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":2050,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Thyroid hormones stimulate bone turnover in adults by increasing osteoclastic bone resorption. TSH suppressive therapy is usually applied in patients with differentiated thyroid cancer (DTC) to improve the disease outcome. Over the last decades several authors have closely monitored the potential harm suffered by the skeletal system. Several studies and meta-analyses have shown that chronic TSH suppressive therapy is safe in premenopausal women and men. Conversely, in postmenopausal women TSH suppressive therapy is associated with a decrease of bone mineral density, deterioration of bone architecture (quantitative CT, QCT; trabecular bone score, TBS), and, possibly, an increased risk of fractures. The TSH receptor is expressed in bone cells and the results of experimental studies in TSH receptor knockout mice and humans on whether low TSH levels, as opposed to solely high thyroid hormone levels, might contribute to bone loss in endogenous or exogenous thyrotoxicosis remain controversial. Recent guidelines on the use of TSH suppressive therapy in patients with DTC give value not only to its benefit on the outcome of the disease, but also to the risks associated with exogenous thyrotoxicosis, namely menopause, osteopenia or osteoporosis, age &amp;gt;60 years, and history of atrial fibrillation. Bone health (BMD and\/or preferably TBS) should be evaluated in postmenopausal women under chronic TSH suppressive therapy or in those patients planning to be treated for several years. Antiresorptive therapy could also be considered in selected cases (increased risk of fracture or significant decline of BMD\/TBS during therapy) to prevent bone loss.<\/jats:p>","DOI":"10.1530\/ec-20-0167","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T09:18:16Z","timestamp":1592558296000},"page":"R158-R172","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-10","source":"Crossref","is-referenced-by-count":39,"title":["TSH suppressive therapy and bone"],"prefix":"10.1530","volume":"9","author":[{"given":"Alessandro","family":"Brancatella","sequence":"first","affiliation":[{"name":"Endocrine Unit 1 1","department":["Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[{"name":"Endocrine Unit 2 2","department":["Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2026070710295528300_bib1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ecl.2018.10.008","article-title":"Thyroid hormone suppression therapy","volume":"48","author":"Biondi","year":"2019","journal-title":"Endocrinology and Metabolism Clinics of North America"},{"key":"2026070710295528300_bib2","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s40618-014-0110-9","article-title":"Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?","volume":"37","author":"Williams","year":"2014","journal-title":"Journal of Endocrinological Investigation"},{"key":"2026070710295528300_bib3","doi-asserted-by":"crossref","first-page":"25103","DOI":"10.1074\/jbc.R109.041087","article-title":"Cellular and molecular mechanisms of bone remodeling","volume":"285","author":"Raggatt","year":"2010","journal-title":"Journal of Biological Chemistry"},{"key":"2026070710295528300_bib4","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1210\/er.2012-1026","article-title":"The osteocyte: an endocrine cell ... and more","volume":"34","author":"Dallas","year":"2013","journal-title":"Endocrine Reviews"},{"key":"2026070710295528300_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1210\/er.2015-1106","article-title":"Role of thyroid hormones in skeletal development and bone maintenance","volume":"37","author":"Bassett","year":"2016","journal-title":"Endocrine Reviews"},{"key":"2026070710295528300_bib6","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1089\/thy.1998.8.1059","article-title":"Expression of thyrotropin receptor on clonal osteoblast-like rat osteosarcoma cells","volume":"8","author":"Inoue","year":"1998","journal-title":"Thyroid"},{"key":"2026070710295528300_bib7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0092-8674(03)00771-2","article-title":"TSH is a negative regulator of skeletal remodeling","volume":"115","author":"Abe","year":"2003","journal-title":"Cell"},{"key":"2026070710295528300_bib8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/thy.2010.0457","article-title":"The influence of thyroid-stimulating hormone and thyroid-stimulating hormone receptor antibodies on osteoclastogenesis","volume":"21","author":"Ma","year":"2011","journal-title":"Thyroid"},{"key":"2026070710295528300_bib9","doi-asserted-by":"crossref","first-page":"9891","DOI":"10.1073\/pnas.1308336110","article-title":"Genetic confirmation for a central role for TNFalpha in the direct action of thyroid stimulating hormone on the skeleton","volume":"110","author":"Sun","year":"2013","journal-title":"PNAS"},{"key":"2026070710295528300_bib10","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/clinchem\/42.1.140","article-title":"Current status and performance goals for serum thyrotropin (TSH) assays","volume":"42","author":"Spencer","year":"1996","journal-title":"Clinical Chemistry"},{"key":"2026070710295528300_bib11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1080\/078538902321117760","article-title":"Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer","volume":"34","author":"McGriff","year":"2002","journal-title":"Annals of Medicine"},{"key":"2026070710295528300_bib12","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1089\/thy.1998.8.737","article-title":"Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry","volume":"8","author":"Cooper","year":"1998","journal-title":"Thyroid"},{"key":"2026070710295528300_bib13","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1089\/thy.2006.16.1229","article-title":"Outcomes of patients with differentiated thyroid carcinoma following initial therapy","volume":"16","author":"Jonklaas","year":"2006","journal-title":"Thyroid"},{"key":"2026070710295528300_bib14","doi-asserted-by":"crossref","first-page":"3270","DOI":"10.1210\/JC.2015-1346","article-title":"Long-term outcomes following therapy in differentiated thyroid carcinoma: NTCTCS Registry Analysis 1987\u20132012","volume":"100","author":"Carhill","year":"2015","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib15","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.1210\/jc.2010-0161","article-title":"Does postoperative thyrotropin suppression therapy truly decrease recurrence in papillary thyroid carcinoma? A randomized controlled trial","volume":"95","author":"Sugitani","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib16","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1089\/thy.2009.0110","article-title":"Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer","volume":"19","author":"American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer","year":"2009","journal-title":"Thyroid"},{"key":"2026070710295528300_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"2026070710295528300_bib18","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1089\/thy.2017.0177","article-title":"Thyrotropin suppressive therapy for low-risk small thyroid cancer: a propensity score-matched cohort study","volume":"27","author":"Park","year":"2017","journal-title":"Thyroid"},{"key":"2026070710295528300_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporosis International"},{"key":"2026070710295528300_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00198-019-05176-3","article-title":"Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures","volume":"31","author":"Kanis","year":"2020","journal-title":"Osteoporosis International"},{"key":"2026070710295528300_bib21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1359\/jbmr.2002.17.12.2222","article-title":"Prediction of fracture risk in postmenopausal white women with peripheral bone densitometry: evidence from the National Osteoporosis Risk Assessment","volume":"17","author":"Miller","year":"2002","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070710295528300_bib22","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/0002-9343(87)90219-1","article-title":"Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine","volume":"82","author":"Ross","year":"1987","journal-title":"American Journal of Medicine"},{"key":"2026070710295528300_bib23","first-page":"818","article-title":"Carefully monitored levothyroxine suppressive therapy is not associated with bone loss in premenopausal women","volume":"78","author":"Marcocci","year":"1994","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib24","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.surg.2011.09.013","article-title":"Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: a prospective controlled study","volume":"150","author":"Sugitani","year":"2011","journal-title":"Surgery"},{"key":"2026070710295528300_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1359\/jbmr.1997.12.1.72","article-title":"Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine","volume":"12","author":"Marcocci","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070710295528300_bib26","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1530\/eje.0.1300350","article-title":"Changes in bone mass during prolonged subclinical hyperthyroidism due to L-thyroxine treatment: a meta-analysis","volume":"130","author":"Faber","year":"1994","journal-title":"European Journal of Endocrinology"},{"key":"2026070710295528300_bib27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1089\/thy.2006.16.583","article-title":"The effects of thyrotropin-suppressive therapy on bone metabolism in patients with well-differentiated thyroid carcinoma","volume":"16","author":"Heemstra","year":"2006","journal-title":"Thyroid"},{"key":"2026070710295528300_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1634\/theoncologist.2015-0179","article-title":"Effect of thyrotropin suppression therapy on bone in thyroid cancer patients","volume":"21","author":"Papaleontiou","year":"2016","journal-title":"Oncologist"},{"key":"2026070710295528300_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.11005\/jbm.2019.26.1.51","article-title":"Influence of thyroid-stimulating hormone suppression therapy on bone mineral density in patients with differentiated thyroid cancer: a meta-analysis","volume":"26","author":"Yoon","year":"2019","journal-title":"Journal of Bone Metabolism"},{"key":"2026070710295528300_bib30","first-page":"922","article-title":"TSH-suppressive therapy can reduce bone mineral density in patients with differentiated thyroid carcinoma: a meta-analysis","volume":"24","author":"Wang","year":"2020","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"2026070710295528300_bib31","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s002230020041","article-title":"Bone mineral density in male patients with L-thyroxine suppressive therapy and Graves disease","volume":"69","author":"Jodar","year":"2001","journal-title":"Calcified Tissue International"},{"key":"2026070710295528300_bib32","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.1994.03510400031027","article-title":"Thyroid hormone use and bone mineral density in elderly women. Effects of estrogen","volume":"271","author":"Schneider","year":"1994","journal-title":"JAMA"},{"key":"2026070710295528300_bib33","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1089\/thy.2014.0287","article-title":"Thyrotropin suppression increases the risk of osteoporosis without decreasing recurrence in ATA low- and intermediate-risk patients with differentiated thyroid carcinoma","volume":"25","author":"Wang","year":"2015","journal-title":"Thyroid"},{"key":"2026070710295528300_bib34","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1210\/jc.2009-1625","article-title":"Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy","volume":"95","author":"Flynn","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00198-005-0027-4","article-title":"The effect of age and bone mineral density on the absolute, excess, and relative risk of fracture in postmenopausal women aged 50\u201399: results from the National Osteoporosis Risk Assessment (NORA)","volume":"17","author":"Siris","year":"2006","journal-title":"Osteoporosis International"},{"key":"2026070710295528300_bib36","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality \u2013 the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"New England Journal of Medicine"},{"key":"2026070710295528300_bib37","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1002\/jemt.20501","article-title":"Trabecular bone microarchitecture is related to the number of risk factors and etiology in osteoporotic men","volume":"70","author":"Legrand","year":"2007","journal-title":"Microscopy Research and Technique"},{"key":"2026070710295528300_bib38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-16-0340","article-title":"Treatment of acromegaly increases BMD but reduces trabecular bone score: a longitudinal study","volume":"175","author":"Godang","year":"2016","journal-title":"European Journal of Endocrinology"},{"key":"2026070710295528300_bib39","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11657-015-0244-1","article-title":"The risk factors for fractures and trabecular bone-score value in patients with endogenous Cushing\u2019s syndrome","volume":"10","author":"Belaya","year":"2015","journal-title":"Archives of Osteoporosis"},{"key":"2026070710295528300_bib40","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/EJE-13-0305","article-title":"Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism","volume":"169","author":"Eller-Vainicher","year":"2013","journal-title":"European Journal of Endocrinology"},{"key":"2026070710295528300_bib41","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1002\/art.11283","article-title":"Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy","volume":"48","author":"Van Staa","year":"2003","journal-title":"Arthritis and Rheumatism"},{"key":"2026070710295528300_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/MED.0000000000000365","article-title":"Utility of trabecular bone score in the evaluation of osteoporosis","volume":"24","author":"Martineau","year":"2017","journal-title":"Current Opinion in Endocrinology, Diabetes, and Obesity"},{"key":"2026070710295528300_bib43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.bone.2015.05.016","article-title":"Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice","volume":"78","author":"Harvey","year":"2015","journal-title":"Bone"},{"key":"2026070710295528300_bib44","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s00198-015-3270-3","article-title":"High-normal free thyroxine levels are associated with low trabecular bone scores in euthyroid postmenopausal women","volume":"27","author":"Hwangbo","year":"2016","journal-title":"Osteoporosis International"},{"key":"2026070710295528300_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1055\/a-0633-2814","article-title":"High serum fractalkine is associated with lower trabecular bone score in premenopausal women with Graves\u2019 disease.","volume":"50","author":"Kuzma","year":"2018","journal-title":"Hormone and Metabolic Research"},{"key":"2026070710295528300_bib46","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12020-018-1671-8","article-title":"Low trabecular bone score in postmenopausal women with differentiated thyroid carcinoma after long-term TSH suppressive therapy","volume":"62","author":"De Mingo Dominguez","year":"2018","journal-title":"Endocrine"},{"key":"2026070710295528300_bib47","first-page":"78","article-title":"The effect of TSH suppression on vertebral trabecular bone scores in patients with differentiated thyroid carcinoma","volume":"102","author":"Moon","year":"2017","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib48","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11914-013-0140-9","article-title":"High-resolution peripheral quantitative computed tomography for the assessment of bone strength and structure: a review by the Canadian Bone Strength Working Group","volume":"11","author":"Cheung","year":"2013","journal-title":"Current Osteoporosis Reports"},{"key":"2026070710295528300_bib49","first-page":"468","article-title":"Review of high-resolution peripheral quantitative computed tomography for the assessment of bone microstructure and strength","volume":"35","author":"Ma","year":"2018","journal-title":"Sheng Wu Yi Xue Gong Cheng Xue Za Zhi"},{"key":"2026070710295528300_bib50","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/cen.12560","article-title":"Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression","volume":"82","author":"Tournis","year":"2015","journal-title":"Clinical Endocrinology"},{"key":"2026070710295528300_bib51","doi-asserted-by":"crossref","first-page":"4232","DOI":"10.1210\/jc.2017-02704","article-title":"Evaluation of bone mineral density using DXA and cQCT in postmenopausal patients under thyrotropin suppressive therapy","volume":"103","author":"Kim","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib52","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/S0140-6736(98)09075-8","article-title":"Mortality after all major types of osteoporotic fracture in men and women: an observational study","volume":"353","author":"Center","year":"1999","journal-title":"Lancet"},{"key":"2026070710295528300_bib53","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","article-title":"Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group","volume":"332","author":"Cummings","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"2026070710295528300_bib54","doi-asserted-by":"crossref","first-page":"2657","DOI":"10.1210\/jc.2014-1051","article-title":"Subclinical thyroid dysfunction and hip fracture and bone mineral density in older adults: the cardiovascular health study","volume":"99","author":"Garin","year":"2014","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib55","doi-asserted-by":"crossref","first-page":"3173","DOI":"10.1210\/jc.2009-2630","article-title":"Thyroid function within the upper normal range is associated with reduced bone mineral density and an increased risk of nonvertebral fractures in healthy euthyroid postmenopausal women","volume":"95","author":"Murphy","year":"2010","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib56","doi-asserted-by":"crossref","first-page":"189","DOI":"10.7326\/M14-0125","article-title":"Subclinical thyroid dysfunction and the risk for fractures: a systematic review and meta-analysis","volume":"161","author":"Wirth","year":"2014","journal-title":"Annals of Internal Medicine"},{"key":"2026070710295528300_bib57","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1001\/jama.2015.5161","article-title":"Subclinical thyroid dysfunction and fracture risk: a meta-analysis","volume":"313","author":"Blum","year":"2015","journal-title":"JAMA"},{"key":"2026070710295528300_bib58","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2265.1992.tb01480.x","article-title":"Morbidity in patients on L-thyroxine: a comparison of those with a normal TSH to those with a suppressed TSH","volume":"37","author":"Leese","year":"1992","journal-title":"Clinical Endocrinology"},{"key":"2026070710295528300_bib59","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1089\/thy.1993.3.17","article-title":"Prevalence of fractures in postmenopausal women with thyroid disease","volume":"3","author":"Solomon","year":"1993","journal-title":"Thyroid"},{"key":"2026070710295528300_bib60","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1359\/jbmr.1997.12.7.1092","article-title":"Fractures after thyroidectomy in men: a population-based cohort study","volume":"12","author":"Nguyen","year":"1997","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070710295528300_bib61","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S8756-3282(00)00379-3","article-title":"Fractures following thyroidectomy in women: a population-based cohort study","volume":"27","author":"Melton","year":"2000","journal-title":"Bone"},{"key":"2026070710295528300_bib62","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1001\/archinte.162.3.338","article-title":"Levothyroxine treatment and occurrence of fracture of the hip","volume":"162","author":"Sheppard","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"2026070710295528300_bib63","doi-asserted-by":"crossref","first-page":"d2238","DOI":"10.1136\/bmj.d2238","article-title":"Levothyroxine dose and risk of fractures in older adults: nested case-control study","volume":"342","author":"Turner","year":"2011","journal-title":"BMJ"},{"key":"2026070710295528300_bib64","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3961\/jpmph.2014.47.1.36","article-title":"Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women","volume":"47","author":"Ko","year":"2014","journal-title":"Journal of Preventive Medicine and Public Health"},{"key":"2026070710295528300_bib65","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bone.2016.03.002","article-title":"Influence of thyroid hormone therapy on the fracture rate \u2013 a claims data cohort study","volume":"86","author":"Viniol","year":"2016","journal-title":"Bone"},{"key":"2026070710295528300_bib66","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1007\/s00268-018-4573-2","article-title":"Is partial or total thyroidectomy associated with risk of long-term osteoporosis: a nationwide population-based study","volume":"42","author":"Hung","year":"2018","journal-title":"World Journal of Surgery"},{"key":"2026070710295528300_bib67","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1089\/thy.1995.5.13","article-title":"Suppressive doses of thyroxine do not accelerate age-related bone loss in late postmenopausal women","volume":"5","author":"Fujiyama","year":"1995","journal-title":"Thyroid"},{"key":"2026070710295528300_bib68","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1530\/eje.1.01933","article-title":"Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma","volume":"153","author":"Heijckmann","year":"2005","journal-title":"European Journal of Endocrinology"},{"key":"2026070710295528300_bib69","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s12020-010-9339-z","article-title":"Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma","volume":"37","author":"Reverter","year":"2010","journal-title":"Endocrine"},{"key":"2026070710295528300_bib70","first-page":"350","article-title":"Ten-year estimated risk of bone fracture in women with differentiated thyroid cancer under TSH-suppressive levothyroxine therapy","volume":"67","author":"Vera","year":"2016","journal-title":"Endokrynologia Polska"},{"key":"2026070710295528300_bib71","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1210\/jc.2017-01986","article-title":"High prevalence of radiological vertebral fractures in women on thyroid-stimulating hormone-suppressive therapy for thyroid carcinoma","volume":"103","author":"Mazziotti","year":"2018","journal-title":"Journal of Clinical Endocrinology and Metabolism"},{"key":"2026070710295528300_bib72","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1080\/03007995.2017.1378174","article-title":"Risk of osteoporosis in thyroid cancer patients using levothyroxine: a population-based study","volume":"34","author":"Lin","year":"2018","journal-title":"Current Medical Research and Opinion"},{"key":"2026070710295528300_bib73","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/jbmr.3407","article-title":"J-shaped association between postoperative levothyroxine dosage and fracture risk in thyroid cancer patients: a retrospective cohort study","volume":"33","author":"Shin","year":"2018","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070710295528300_bib74","author":"National Clinical Guideline Centre (UK).","journal-title":"Osteoporosis: Fragility Fracture Risk: Osteoporosis: Assessing the Risk of Fragility Fracture (NICE Clinical Guidelines, No. 146)"},{"key":"2026070710295528300_bib75","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/thy.2008.0428","article-title":"Osteoporosis and thyrotropin-suppressive therapy: reduced effectiveness of alendronate","volume":"19","author":"Panico","year":"2009","journal-title":"Thyroid"},{"key":"2026070710295528300_bib76","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/j.amjcard.2014.03.008","article-title":"Risk of atrial fibrillation with use of oral and intravenous bisphosphonates","volume":"113","author":"Sharma","year":"2014","journal-title":"American Journal of Cardiology"},{"key":"2026070710295528300_bib77","doi-asserted-by":"crossref","first-page":"3737","DOI":"10.1172\/JCI63948","article-title":"Hyperthyroid-associated osteoporosis is exacerbated by the loss of TSH signaling","volume":"122","author":"Baliram","year":"2012","journal-title":"Journal of Clinical Investigation"},{"key":"2026070710295528300_bib78","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1359\/jbmr.070302","article-title":"Thyroid-stimulating hormone restores bone volume, microarchitecture, and strength in aged ovariectomized rats","volume":"22","author":"Sampath","year":"2007","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070710295528300_bib79","doi-asserted-by":"crossref","first-page":"4289","DOI":"10.1073\/pnas.0712395105","article-title":"Intermittent recombinant TSH injections prevent ovariectomy-induced bone loss","volume":"105","author":"Sun","year":"2008","journal-title":"PNAS"},{"key":"2026070710295528300_bib80","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.1365-2265.2007.03016.x","article-title":"Effects of serum TSH and FT4 levels and the TSHR-Asp727Glu polymorphism on bone: the Rotterdam Study","volume":"68","author":"van der Deure","year":"2008","journal-title":"Clinical Endocrinology"},{"key":"2026070710295528300_bib81","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/cen.13387","article-title":"Mild TSH resistance: clinical and hormonal features in childhood and adulthood","volume":"87","author":"Vigone","year":"2017","journal-title":"Clinical Endocrinology"},{"key":"2026070710295528300_bib82","doi-asserted-by":"crossref","first-page":"e0145292","DOI":"10.1371\/journal.pone.0145292","article-title":"A modest protective effect of thyrotropin against bone loss is associated with plasma triiodothyronine levels","volume":"10","author":"Kim","year":"2015","journal-title":"PLoS ONE"},{"key":"2026070710295528300_bib83","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1359\/JBMR.041126","article-title":"Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma","volume":"20","author":"Mazziotti","year":"2005","journal-title":"Journal of Bone and Mineral Research"},{"key":"2026070710295528300_bib84","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1089\/thy.2007.0166","article-title":"The effects of recombinant TSH on bone turnover markers and serum osteoprotegerin and RANKL levels","volume":"18","author":"Martini","year":"2008","journal-title":"Thyroid"},{"key":"2026070710295528300_bib85","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00774-009-0098-y","article-title":"The effects of recombinant human TSH on bone turnover in patients after thyroidectomy","volume":"28","author":"Karga","year":"2010","journal-title":"Journal of Bone and Mineral Metabolism"},{"key":"2026070710295528300_bib86","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1210\/me.2007-0221","article-title":"A lack of thyroid hormones rather than excess thyrotropin causes abnormal skeletal development in hypothyroidism","volume":"22","author":"Bassett","year":"2008","journal-title":"Molecular Endocrinology"},{"key":"2026070710295528300_bib87","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1002\/jbmr.3426","article-title":"Thyroid stimulating hormone and bone mineral density: evidence from a two-sample Mendelian randomization study and a candidate gene association study","volume":"33","author":"van Vliet","year":"2018","journal-title":"Journal of Bone and Mineral Research"}],"container-title":["Endocrine Connections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ec.bioscientifica.com\/view\/journals\/ec\/9\/7\/EC-20-0167.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/9\/7\/R158\/4656\/ec-20-0167.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article-pdf\/9\/7\/R158\/4656\/ec-20-0167.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:30:12Z","timestamp":1783434612000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/ec\/article\/9\/7\/R158\/699\/TSH-suppressive-therapy-and-boneA-Brancatella-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,1]]},"references-count":87,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7,1]]}},"URL":"https:\/\/doi.org\/10.1530\/ec-20-0167","relation":{},"ISSN":["2049-3614"],"issn-type":[{"value":"2049-3614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,1]]}}}